Utility of intersystem extrapolation factors in early reaction phenotyping and the quantitative extrapolation of human liver microsomal intrinsic clearance using recombinant cytochromes P450

Drug Metabolism and Disposition

Volumn 39, Issue 3, 2011, Pages 373-382

  Chen, Yuan ^a,b   Liu, Liling ^a,c   Nguyen, Khanh ^a   Fretland, Adrian J ^a,c  

^a ROCHE BIOSCIENCE   (United States)

^b GENENTECH INC   (United States)

^c Roche Nutley   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUFURALOL; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DICLOFENAC; FLUOXETINE; HARMINE; IMIPRAMINE; MEPHENYTOIN; METOPROLOL; MIDAZOLAM; MIRTAZAPINE; NIFEDIPINE; OMEPRAZOLE; PACLITAXEL; PHENACETIN; RECOMBINANT PROTEIN; ROSIGLITAZONE; SILDENAFIL; TESTOSTERONE; TOLBUTAMIDE; TOLTERODINE; WARFARIN;

ANALYTIC METHOD; ARTICLE; DRUG CLEARANCE; DRUG METABOLISM; ENZYME KINETICS; HUMAN; HUMAN CELL; INTERSYSTEM EXTRAPOLATION FACTOR; LIVER MICROSOME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; QUANTITATIVE ANALYSIS;

CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS;

EID: 79951930597     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035147     Document Type: Article

References (18)

1. Crespi CL (1995) Xenobiotic metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 26:179-235.
2. Crespi CL and Miller VP (1999) Use of heterologously expressed drug metabolizing enzymes - state of the art and prospects for the future. Pharmacol Ther 84:121-131. (Pubitemid 29488547)
3. Crespi CL and Penman BW (1997) Use of cDNA-expressed human cytochrome P450 enzymes to study potential drug-drug interactions. Adv Pharmacol 43:171-188.
4. Emoto C, Murase S, and Iwasaki K (2006) Approach to the prediction of the contribution of major cytochrome P450 enzymes to drug metabolism in the early drug-discovery stage. Xenobiotica 36:671-683. (Pubitemid 44195982)
5. Howgate EM, Rowland Yeo K, Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2006) Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36:473-497. (Pubitemid 43890728)
6. Kerr BM, Thummel KE, Wurden CJ, Klein SM, Kroetz DL, Gonzalez FJ, and Levy RH (1994) Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 47:1969-1979.
7. Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T, Tani M, Yamamoto T, Ishizaki T, and Kuroiwa Y (1997) Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280:927-933. (Pubitemid 27171357)
8. Margolis JM, O'Donnell JP, Mankowski DC, Ekins S, and Obach RS (2000) (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug Metab Dispos 28:1187-1191.
9. Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, and Yokoi T (1999) Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: evaluation of approach to predict the contribution of multiple CYPs. Drug Metab Dispos 27:1381-1391.
10. Obach RS (1999) Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Dispos 27:1350-1359.
11. Proctor NJ, Tucker GT, and Rostami-Hodjegan A (2004) Predicting drug clearance from recombinantly expressed CYPs: intersystem extrapolation factors. Xenobiotica 34:151-178. (Pubitemid 38299716)
12. Rowland-Yeo K, Rostami-Hodjega A, and Tucker GT (2003) Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 57:687-688.
13. Störmer E, von Moltke LL, and Greenblatt DJ (2000a) Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exp Ther 295:793-801.
14. Störmer E, von Moltke LL, Shader RI, and Greenblatt DJ (2000b) Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28:1168-1175.
15. Venkatakrishnan K, von Moltke LL, and Greenblatt DJ (1998) Relative quantities of catalytically active CYP 2C9 and 2C19 in human liver microsomes: application of the relative activity factor approach. J Pharm Sci 87:845-853. (Pubitemid 28319415)
16. Venkatakrishnan K, von Moltke LL, Court MH, Harmatz JS, Crespi CL, and Greenblatt DJ (2000) Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493-1504.
17. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Venkatakrishnan K, Schmider J, Harmatz JS, and Shader RI (1998) Multiple human cytochromes contribute to biotransformation of dextromethorphan in-vitro: role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. J Pharm Pharmacol 50:997-1004. (Pubitemid 28464085)
18. Yu AM, Idle JR, Krausz KW, Küpfer A, and Gonzalez FJ (2003) Contribution of individual cytochrome P450 isozymes to the O-demethylation of the psychotropic β-carboline alkaloids harmaline and harmine. J Pharmacol Exp Ther 305:315-322. (Pubitemid 36373866)